endTB-Q trial: a caveat on confounding by baseline drug resistance - Author's reply

Lorenzo Guglielmetti; Maelenn Gouillou; Praharshinie Rupasinghe; Carole D. Mitnick

doi:10.1016/S2213-2600(26)00152-9

endTB-Q trial: a caveat on confounding by baseline drug resistance - Author's reply

Lorenzo Guglielmetti
, Maelenn Gouillou
, Praharshinie Rupasinghe
, Carole D. Mitnick

Mycobacteriology

Research output: Contribution to journal › Letter

Original language	English
Journal	Lancet Respiratory Medicine
Volume	14
Issue number	6
Pages (from-to)	e37-e38
Number of pages	2
ISSN	2213-2600
DOIs	https://doi.org/10.1016/S2213-2600(26)00152-9
Publication status	Published - 2-Jun-2026

Access to Document

10.1016/S2213-2600(26)00152-9

Cite this

@article{6d56fcfc6a824409acded124c4be1642,

title = "endTB-Q trial: a caveat on confounding by baseline drug resistance - Author's reply",

author = "Lorenzo Guglielmetti and Maelenn Gouillou and Praharshinie Rupasinghe and Mitnick, \{Carole D.\}",

year = "2026",

month = jun,

day = "2",

doi = "10.1016/S2213-2600(26)00152-9",

language = "English",

volume = "14",

pages = "e37--e38",

journal = "Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - endTB-Q trial: a caveat on confounding by baseline drug resistance - Author's reply

AU - Guglielmetti, Lorenzo

AU - Gouillou, Maelenn

AU - Rupasinghe, Praharshinie

AU - Mitnick, Carole D.

PY - 2026/6/2

Y1 - 2026/6/2

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=itm_wosliteitg&SrcAuth=WosAPI&KeyUT=WOS:001788443700001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/S2213-2600(26)00152-9

DO - 10.1016/S2213-2600(26)00152-9

M3 - Letter

C2 - 42140219

SN - 2213-2600

VL - 14

SP - e37-e38

JO - Lancet Respiratory Medicine

JF - Lancet Respiratory Medicine

IS - 6

ER -

endTB-Q trial: a caveat on confounding by baseline drug resistance - Author's reply

Access to Document

Other files and links

Cite this